New Key Statistics Module, Z-Score and F-Score
OTCPK:NAVB Key Ratios
| Market Cap $ M | 3.50 |
| Enterprise Value $ M | 0.90 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | -- |
| Price/Sales | -- |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | -- |
| EPS (TTM) $ | -0.06 |
| Beneish M-Score | 2.71 |
| 10-y EBITDA Growth Rate % | 25.40 |
| 5-y EBITDA Growth Rate % | 25.80 |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -0.10 |
| EV-to-EBITDA | -0.10 |
| PEG | -- |
| Shares Outstanding M | 100.08 |
| Net Margin (%) | -118,200.00 |
| Operating Margin % | -1,017,900.00 |
| Pre-tax Margin (%) | -860,600.00 |
| Quick Ratio | 0.51 |
| Current Ratio | 0.56 |
| ROA % (ttm) | -21.96 |
| ROE % (ttm) | -- |
| ROIC % (ttm) | -357.48 |
| Dividend Yield % | -- |
| Altman Z-Score | -99.89 |
| Piotroski F-Score | 2.00 |
| Positive ROA | N |
| Positive CFROA | N |
| Higher ROA y-y | Y |
| Cash flow > Earnings | N |
| Lower Leverage y-y | Y |
| Higher Current Ratio y-y | N |
| Less Shares Outstanding y-y | N |
| Gross Margin Increase y-y | N |
| Higher Asset Turnover y-y | N |
NAVB Number of Guru Trades
NAVB Volume of Guru Trades
Gurus Latest Trades with OTCPK:NAVB
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
OTCPK:NAVB is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Navidea Biopharmaceuticals Inc Insider Transactions
No Available Data
News about OTCPK:NAVB
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers